Twynsta Shortage: What Providers and Prescribers Need to Know in 2026

Patients on Twynsta are presenting at clinics and pharmacies throughout 2026 unable to fill their prescriptions. This guide provides clinicians with the key facts about the Twynsta discontinuation, preferred substitution strategies, and a framework for patient communication.

Clinical Summary: What Happened to Twynsta?

Twynsta (telmisartan/amlodipine) is a fixed-dose combination antihypertensive containing a dihydropyridine CCB (amlodipine) and an angiotensin II receptor blocker (telmisartan). Originally FDA-approved in October 2009 by Boehringer Ingelheim, the brand was voluntarily discontinued by the manufacturer. The FDA lists all four tablet strengths (40/5 mg, 40/10 mg, 80/5 mg, and 80/10 mg) under discontinued status.

Generic telmisartan/amlodipine remains available from a limited number of manufacturers (including Lupin Pharmaceuticals), but the supply is inconsistent. Many retail pharmacies do not stock it, and patients are experiencing significant access difficulties.

Pharmacological Profile: Telmisartan and Amlodipine

Telmisartan: A selective AT1 receptor antagonist with one of the longest plasma half-lives among ARBs (~24 hours). At 80 mg, inhibits the pressor response to angiotensin II infusion by ~90% at peak with ~40% inhibition persisting for 24 hours. Also has partial PPAR-gamma agonist activity, which may offer metabolic benefits in some patients.

Amlodipine: A dihydropyridine CCB with a long plasma half-life (~35–50 hours) and slow onset of action. Lowers blood pressure through arteriolar vasodilation; does not significantly affect cardiac conduction or contractility at therapeutic doses.

The combination targets peripheral vascular resistance through two complementary, non-redundant mechanisms, producing additive antihypertensive effects with a favorable tolerability profile. ARB co-administration has been shown to attenuate the peripheral edema associated with CCB monotherapy.

Therapeutic Substitution Options

When Twynsta cannot be filled, consider the following substitution strategies in consultation with your patient's clinical profile:

Generic amlodipine + generic telmisartan (separate prescriptions): Pharmacologically identical. No dose adjustment required. This is typically the fastest and most accessible solution. Both components are widely available at virtually all pharmacies.

Amlodipine/valsartan (Exforge generic): Closest fixed-dose combination substitute. Valsartan is Class I ARB evidence for hypertension. Well tolerated; widely available. Note valsartan's shorter half-life vs. telmisartan — clinical significance is generally minimal for hypertension.

Amlodipine/olmesartan (Azor generic): May be preferred for patients with more resistant hypertension. Olmesartan has a strong receptor binding affinity with data supporting superior BP reduction in some resistant HTN populations.

Amlodipine/benazepril (Lotrel generic): ACE inhibitor + CCB option. Appropriate if ACE inhibitor is clinically preferred (e.g., proteinuric CKD, diabetic nephropathy). Avoid if patient previously switched to ARB due to ACE inhibitor-induced cough. Risk of dry cough ~10–15%; angioedema risk lower than with ACE inhibitors used alone.

Dose Equivalence Guidance

When switching between ARBs, approximate equivalence is based on clinical data rather than strict mg-to-mg conversion. General ARB equivalences commonly used in practice:

Telmisartan 40 mg ≈ Valsartan 80 mg ≈ Olmesartan 10–20 mg

Telmisartan 80 mg ≈ Valsartan 160–320 mg ≈ Olmesartan 20–40 mg

Monitor blood pressure 2–4 weeks after any substitution and adjust dose as needed. ARB inter-class switching is generally well tolerated.

Key Drug Interactions and Monitoring Parameters

When prescribing any telmisartan/amlodipine-equivalent, maintain awareness of the following:

Aliskiren: Contraindicated with any ARB in patients with diabetes; avoid in patients with GFR <60 mL/min

ACE inhibitors: Dual RAAS blockade significantly increases risk of hypotension, hyperkalemia, and acute renal failure — avoid combination

Digoxin: Telmisartan increases digoxin peak (49%) and trough (20%) levels — monitor levels when initiating, adjusting, or discontinuing

Lithium: ARBs may cause reversible lithium toxicity — monitor serum lithium levels

NSAIDs: May attenuate antihypertensive effect and increase risk of renal impairment

Patient Communication Framework

When counseling patients about this transition, consider the following talking points:

"The brand-name Twynsta is no longer being made, but we can get you the same two active ingredients with a simple prescription change."

"Taking amlodipine and telmisartan as separate tablets is clinically identical and will likely cost you less."

"We'll check your blood pressure in 2–4 weeks after any change to make sure your numbers remain controlled."

Resources for Providers

For providers who want to help patients find pharmacies that have the generic telmisartan/amlodipine in stock, medfinder for providers offers a structured solution: patients provide their medication, strength, and zip code, and medfinder contacts local pharmacies to identify which ones have it available.